BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29131545)

  • 21. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
    Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
    Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
    Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage.
    Schulman JJ; Wright FA; Kaufmann T; Wojcikiewicz RJH
    J Biol Chem; 2013 Aug; 288(35):25340-25349. PubMed ID: 23884412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
    Zhong F; Harr MW; Bultynck G; Monaco G; Parys JB; De Smedt H; Rong YP; Molitoris JK; Lam M; Ryder C; Matsuyama S; Distelhorst CW
    Blood; 2011 Mar; 117(10):2924-34. PubMed ID: 21193695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.
    Vervliet T; Parys JB; Bultynck G
    Biochem Soc Trans; 2015 Jun; 43(3):396-404. PubMed ID: 26009182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the anti-apoptotic mechanism of Bcl-B.
    Zhai D; Ke N; Zhang H; Ladror U; Joseph M; Eichinger A; Godzik A; Ng SC; Reed JC
    Biochem J; 2003 Nov; 376(Pt 1):229-36. PubMed ID: 12921534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis.
    Hirotani M; Zhang Y; Fujita N; Naito M; Tsuruo T
    J Biol Chem; 1999 Jul; 274(29):20415-20. PubMed ID: 10400666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca
    Kerkhofs M; La Rovere R; Welkenhuysen K; Janssens A; Vandenberghe P; Madesh M; Parys JB; Bultynck G
    Cell Calcium; 2021 Mar; 94():102333. PubMed ID: 33450506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Stability and Expression Level of Bok Are Governed by Binding to Inositol 1,4,5-Trisphosphate Receptors.
    Schulman JJ; Wright FA; Han X; Zluhan EJ; Szczesniak LM; Wojcikiewicz RJ
    J Biol Chem; 2016 May; 291(22):11820-8. PubMed ID: 27053113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties.
    Vervliet T; Lemmens I; Welkenhuyzen K; Tavernier J; Parys JB; Bultynck G
    Biochem Biophys Res Commun; 2015 Jul; 463(3):174-9. PubMed ID: 25957473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
    de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca2+ signaling.
    Eckenrode EF; Yang J; Velmurugan GV; Foskett JK; White C
    J Biol Chem; 2010 Apr; 285(18):13678-84. PubMed ID: 20189983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP
    Distelhorst CW; Bootman MD
    Cold Spring Harb Perspect Biol; 2019 Sep; 11(9):. PubMed ID: 31110129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death.
    Reed JC; Zha H; Aime-Sempe C; Takayama S; Wang HG
    Adv Exp Med Biol; 1996; 406():99-112. PubMed ID: 8910675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.
    Gabellini C; De Luca T; Trisciuoglio D; Desideri M; Di Martile M; Passeri D; Candiloro A; Biffoni M; Rizzo MG; Orlandi A; Del Bufalo D
    Carcinogenesis; 2013 Nov; 34(11):2558-67. PubMed ID: 23836782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.
    Vervloessem T; Akl H; Tousseyn T; De Smedt H; Parys JB; Bultynck G
    Oncotarget; 2017 Dec; 8(67):111656-111671. PubMed ID: 29340082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-2 binds to and inhibits ryanodine receptors.
    Vervliet T; Decrock E; Molgó J; Sorrentino V; Missiaen L; Leybaert L; De Smedt H; Kasri NN; Parys JB; Bultynck G
    J Cell Sci; 2014 Jun; 127(Pt 12):2782-92. PubMed ID: 24762814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth.
    Trisciuoglio D; De Luca T; Desideri M; Passeri D; Gabellini C; Scarpino S; Liang C; Orlandi A; Del Bufalo D
    Neoplasia; 2013 Mar; 15(3):315-27. PubMed ID: 23479509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptosis regulation by Bcl-x(L) modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating.
    Li C; Wang X; Vais H; Thompson CB; Foskett JK; White C
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12565-70. PubMed ID: 17636122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain.
    Vervliet T; Lemmens I; Vandermarliere E; Decrock E; Ivanova H; Monaco G; Sorrentino V; Nadif Kasri N; Missiaen L; Martens L; De Smedt H; Leybaert L; Parys JB; Tavernier J; Bultynck G
    Sci Rep; 2015 Apr; 5():9641. PubMed ID: 25872771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.